Apr 102018


On April 10th, the representatives of Novartis paid a visit to the Almazov Centre. The delegation was led by the new Novartis CEO Vas Narasimhan and included Nikolaos Tripodis, Managing Director of Novartis Pharma Russia, Vadim Vlasov, President of Novartis Group Russia, Tatyana Loginova, Head of Strategy and Government Affairs at Novartis Group Russia, and Vitaly Brizhagin, Head of Healthcare Systems at Novartis Pharma Russia.

The guests started with a tour around the Preclinical Translational Research Centre where Mikhail Galagudza, Director of the Experimental Medicine Institute, showed them the advantages of the Almazov Centre in conducting the preclinical trials of new drugs and the    available facilities for medical and biological research in general.

The program also included a visit to the Institute of Molecular Biology and Genetics where Anna Kostareva, Director of the Institute, presented the current fields of research and the possibilities for joint research projects.

The visit ended with a meeting with Professor Evgeny Shlyakhto, Director General of the Almazov Centre. It was attended by Alexandra Konradi, Deputy Director General for Research, Mikhail Karpenko, Deputy Director General for Science and Clinic as well as directors of all research institutes of the Centre. During the meeting, the participants discussed the possible areas of joint research and cooperation to promote the principles of value-based medicine in the Russian medical community.